TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03982238
Drug: Insulin
Normalized name: Insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous subcutaneous insulin infusion therapy for 1 month
Study: NCT03982238
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Continuous subcutaneous insulin infusion plus metformin (at least1000mg/day) for 1 month
Study: NCT03982238
Drug: Dapagliflozin
Normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Continuous subcutaneous insulin infusion plus metformin (10mg/day) for 1 month
Study: NCT01010854
Drug: VPA FEC100
Normalized name: VPA
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral VPA (60 mg/kg bid) q 12h X 6 with IV 5-Fluorouracil (500 mg/m2) Epirubicin (100 mg/m2) and Cyclophosphamide (500 mg/m2)
Study: NCT01677507
Drug: Variation in eye pressure response to timolol and latanoprost treatment
Normalized name: latanoprost / timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Arm 1 is to test for variation in eye pressure response to timolol. Arm 2 is to test for variation in eye pressure response to latanoprost.
Study: NCT04172311
Drug: Levetiracetam
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levetiracetam is a second generation anti-epileptic drug which is broad spectrum and commonly used as add-on in refractory epilepsy
Study: NCT00861588
Drug: isoflavones (Soylife 25)
Normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40mg of soy isoflavones capsule (once daily)
Study: NCT00340834
Drug: Fingolimod 1.25 mg
DrugBank: Fingolimod (DB08868)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Core: Patients self-administered fingolimod 1.25 mg capsules orally once daily. In addition, they self-administered an interferon β-1a placebo intramuscular (im) injection once weekly.~Extension: Patients self-administered fingolimod 1.25 mg capsules orally once daily until switched to 0.5 mg capsules upon study protocol amendment.
Study: NCT00340834
Drug: Fingolimod 0.5 mg
Normalized name: fingolimod 0.5 MG
DrugBank: Fingolimod (DB08868)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Core: Patients self-administered fingolimod 0.5 mg capsules orally once daily. In addition, they self-administered an interferon β-1a placebo intramuscular (im) injection once weekly.~Extension: Patients self-administered fingolimod 0.5 mg capsules orally once daily.
Study: NCT00340834
Drug: Interferon β-1a 30 µg
Normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Core: Patients self-administered interferon β-1a 30 μg in an intramuscular (im) injection once weekly. In addition, they self-administered a fingolimod placebo capsule orally once daily.~Extension: Patients self-administered either fingolimod 1.25 mg or 0.5 mg capsules orally once daily until switched to 0.5 mg capsules upon study protocol amendment.
Study: NCT02825147
Drug: Pegaspargase
Normalized name: pegaspargase
DrugBank: Pegaspargase (DB00059)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02825147
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02825147
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02173392
Drug: Brodalumab
Normalized name: Brodalumab
DrugBank: Brodalumab (DB11776)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Brodalumab is a large molecule for the treatment of inflammatory diseases
Study: NCT01287546
Drug: LY2875358 + erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Part A2 Dose escalation of LY2875358 administered IV, on Day 1 and 15 every 28 days for at least two cycles in combination with daily erlotinib dosing (150 mg) taken orally (PO).
Study: NCT01287546
Drug: LY2875358 at Part A highest dose
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part B (Dose Exploration): LY2875358 at Part A highest dose administered IV, on Day 1 and 15 every 28 days for at least two cycles.
Study: NCT01287546
Drug: LY2875358 at Part A highest dose + trametinib
Normalized name: Tramétinib
DrugBank: Trametinib (DB08911)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Part B (in combination with trametinib): LY2875358 at Part A highest dose administered IV, on Day 1 and 15 every 28 days for at least two cycles, in combination with trametinib at 2 mg orally once daily
Study: NCT00209170
Drug: Escitalopram
Normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Escitalopram is a selective serotonin reuptake inhibitor (SSRI) antidepressant. It's a 10 mg pill taken once or twice daily for 6 months.
Study: NCT02317341
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single intravenous dose
Study: NCT02317341
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single intravenous dose given over 40 minutes
Study: NCT02317341
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given intravenously over 40 minutes
Study: NCT02317341
Drug: Midazolam(placebo)
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given intravenously over 40 minutes
Study: NCT01933256
Drug: HIP2B
Normalized name: Hydroxyindole-2-carboxylic acid
DrugBank: Indole (DB04532)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00645918
Drug: clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: oral, 75 mg daily for 6 months starting on day of randomization
Study: NCT00645918
Drug: clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: oral, 450 mg loading dose on day of randomization; 75 mg daily for 6 months starting on day of randomization
Study: NCT02538367
Drug: Prucalopride 2mg
Normalized name: PRUCALOPRIDE 2MG TAB
DrugBank: Prucalopride (DB06480)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00418379
Drug: 300 IR (4M)
Normalized name: orchard grass pollen extract
DrugBank: Dactylis glomerata pollen (DB10379)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 IR grass pollen allergen extract tablet starting 4 months before the pollen season
Study: NCT00418379
Drug: 300 IR (2M)
Normalized name: orchard grass pollen extract
DrugBank: Dactylis glomerata pollen (DB10379)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 IR grass pollen allergen extract tablet starting 2 months before the pollen season
Study: NCT03061045
Drug: Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Intravenous Powder for Suspension [LUMASON]
DrugBank: Sulfur hexafluoride (DB11104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patients enrolled in this study will undergo contrast enhanced ultrasound examination for assessment of brain perfusion.
Study: NCT02029638
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine at dose 30 mg/m\^2 will be administered daily by intravenous infusion over 30 minutes on Day -6 to Day -2.
Study: NCT02029638
Drug: diphenhydramine
Normalized name: Diphenhydramine
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25mg diphenhydramine orally prior to antithymocyte globulin infusion.
Study: NCT02029638
Drug: methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: On Days -9 to -7 methylprednisolone 1mg/kg IV 1 hour prior ATG. This dose may be repeated once 3 hours after the first dose of steroids. On Day -6 and -5, methylprednisolone 0.75 mg/kg/ IV as a single dose; on Days -4 and -3, methylprednisolone 0.5 mg/kg/ IV as a single dose; on Day -2 methylprednisolone 0.25 mg/kg/ IV as a single dose.
Study: NCT02029638
Drug: MESNA
Normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A series of MESNA doses will be administered for each dose of high dose, post-transplant cyclophosphamide. The total daily dose of MESNA is equal to 80% of the total daily dose of cyclophosphamide.
Study: NCT02029638
Drug: mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MMF will be administered at a dose of 15 mg/kg orally three times per day based upon actual body weight, with the maximum of 3 grams a day from Day 5 to 35. The dose will then be reduced to the standard 1 g twice daily thereafter.
Study: NCT02029638
Drug: prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone will be administered at a dose of 10 mg orally daily from Day 5 for 12 weeks. Thereafter the dose will be reduced to 5 mg orally daily.
Study: NCT02029638
Drug: filgrastim
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: All recipients will receive 5 microgram/kg per day of filgrastim as a single, subcutaneous injection from Day 5 post-transplant until the absolute neutrophil count is greater than 1000/µl on three consecutive measurements over at least 2 days.
Study: NCT03024840
Drug: Sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevoflurane: 1%\~2%
Study: NCT03024840
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol: 9-15 mg/kg/h
Study: NCT00691093
Drug: fesoterodine
Normalized name: Fesoterodine
DrugBank: Fesoterodine (DB06702)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4 mg per 24 hours, possibility to increase to 8 mg depending on efficacy chronic treatment
Study: NCT00684112
Drug: Gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients in this arm of the study will receive two identical capsules, containing 300 mg of oral gabapentin each, 1 hour before surgery.
Study: NCT02600741
Drug: Paliperidone palmitate
Normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients enrolled in this study will continue to receive routine treatment of paliperidone palmitate, as directed by their treating physician.
Study: NCT02600741
Drug: Chlorpromazine
Normalized name: Chlorpromazine
DrugBank: Chlorpromazine (DB00477)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
Study: NCT02600741
Drug: Droperidol
Normalized name: Droperidol
DrugBank: Droperidol (DB00450)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
Study: NCT02600741
Drug: Fluphenazine
Normalized name: Fluphenazine
DrugBank: Fluphenazine (DB00623)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
Study: NCT02600741
Drug: Haloperidol
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
Study: NCT02600741
Drug: Loxapine
Normalized name: Loxapine
DrugBank: Loxapine (DB00408)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
Study: NCT02600741
Drug: Perphenazine
Normalized name: Perphenazine
DrugBank: Perphenazine (DB00850)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
Study: NCT02600741
Drug: Pimozide
Normalized name: Pimozide
DrugBank: Pimozide (DB01100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
Study: NCT02600741
Drug: Prochlorperazine
Normalized name: Prochlorperazine
DrugBank: Prochlorperazine (DB00433)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
Study: NCT02600741
Drug: Thiothixene
Normalized name: Thiothixene
DrugBank: Thiothixene (DB01623)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
Study: NCT02600741
Drug: Thioridazine
Normalized name: Thioridazine
DrugBank: Thioridazine (DB00679)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
Study: NCT02600741
Drug: Trifluoperazine
Normalized name: Trifluoperazine
DrugBank: Trifluoperazine (DB00831)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
Study: NCT02600741
Drug: Aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
Study: NCT02600741
Drug: Asenapine
Normalized name: Asenapine
DrugBank: Asenapine (DB06216)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
Study: NCT02600741
Drug: Clozapine
Normalized name: Clozapine
DrugBank: Clozapine (DB00363)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
Study: NCT02600741
Drug: Iloperidone
Normalized name: Iloperidone
DrugBank: Iloperidone (DB04946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
Study: NCT02600741
Drug: Olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
Study: NCT02600741
Drug: Paliperidone
Normalized name: Paliperidone
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
Study: NCT02600741
Drug: Quetiapine
Normalized name: Quetiapine
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
Study: NCT02600741
Drug: Risperidone
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
Study: NCT02600741
Drug: Ziprasidone
Normalized name: Ziprasidone
DrugBank: Ziprasidone (DB00246)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
Study: NCT03395223
Drug: Methylene Blue
Normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of Methylene Blue to treat acquired methaemoglobinaemia
Study: NCT02335580
Drug: Somatostatin and its analogs
Normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin and/or octreotide will be intravenously infused.
Study: NCT03120637
Drug: Methylene Blue
Normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00206778
Drug: Lamotrigine
Normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00206778
Drug: Sodium Valproate
Normalized name: sodium valproate
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00553553
Drug: Morphine sulphate
Normalized name: Morphine sulphate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous morphine titrated up to 0.25 milligrams/kilogram prior to end of resection phase or within first 2 hours of surgery
Study: NCT00425477
Drug: bexarotene
Normalized name: Bexarotene
DrugBank: Bexarotene (DB00307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01797991
Drug: Dexamethasone per os
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01797991
Drug: Matching placebo for dexamethasone IV
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01797991
Drug: Dexamethasone IV
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01797991
Drug: Matching placebo for dexamethasone per os
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04198233
Drug: Diazepam
Normalized name: Diazepam
DrugBank: Diazepam (DB00829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diazepam 10 mg compounded suppository
Study: NCT00685529
Drug: Racemic formoterol
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 12 µg of racemic formoterol fumarate BID
Study: NCT00685529
Drug: Arformoterol tartrate inhalation solution
Normalized name: ARFORMOTEROL TARTRATE 15 ug in 2 mL RESPIRATORY (INHALATION) SOLUTION [Arformoterol Tartrate Inhalation Solution]
DrugBank: Arformoterol (DB01274)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15 µg of nebulized arformoterol tartrate inhalation solution BID
Study: NCT00685529
Drug: Racemic formoterol
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 24 µg of racemic formoterol fumarate BID
Study: NCT00776555
Drug: Lisdexamfetamine Dimesylate
Normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Study is a two-period cross-over design where subjects will have 2 Screening visits, a Baseline visit, and then be enrolled into the study for 2 Periods. Each Period has 2-3 visits and lasts from 2-6 weeks. At each Period visit subjects will be given one of the two treatment arm drugs that have been solubilized and then have blood drawn for pharmacokinetic analysis and the Drug Rating Questionnaire administered. At the end of Period 1 subjects will be crossed-over to the alternative treatment drug for the Period 2. The Vyvanse™ capsule contents will emptied into water to make a solution and given to subjects to drink at the beginning of each Period visit.
Study: NCT00776555
Drug: Racemic mixture of dextroamphetamine and lisdexamfetamine
Normalized name: brown mixture
DrugBank: Amphetamine (DB00182)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Same visits as described for Vyvanse™. The ADDERALL XR® capsule contents will be crushed, solubilized with water, and given to subjects to drink prior to pharmacokinetic blood draws and DRQ-S administration over the course of two periods.
Study: NCT02086721
Drug: L19-IL2
Normalized name: L19-IL2
DrugBank: Darleukin (DB17157)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive a schedule of 1 x 30 Gy, 3 x 15-20 Gy; 5 x 12 Gy; 8 x 7.5 Gy; to the 80 % or 100 % isodose.~Step -1: Toxicity of 10 Mio IU of L19-IL2 (n=3-6)10 Mio IU of L19-IL2 (max. 6 cycles) via i.v. bolus injection.~Toxicity scored at every i.v. drug administration and on day 7, 14 and 21. Step 1: Toxicity of 15 Mio IU of L19-IL2 (n=3-6)(max. 6 cycles) via i.v. bolus injection.~Step 2: Toxicity of 22.5 Mio IU of L19-IL2 (n=3-6)(max. 6 cycles) via i.v. bolus injection.~Toxicity scored at every i.v. drug administration and on day 7, 14 and 21 of the cycle.~Step 3: Expansion cohort of the maximally tolerable dose (n=10) Administration of the maximally tolerable dose of L19-IL2(max. 6 cycles) via i.v. bolus injection.~Toxicity scored at every i.v. drug administration and on day 7, 14 and 21 of the cycle.
Study: NCT02491398
Drug: Bendamustine + Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01769703
Drug: Dabigatran 110/150 mg BID
DrugBank: Dabigatran (DB14726)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabigatran will be taken bid for 30 days post enrolment. The dose of dabigatran will be based on patient age and renal function.
Study: NCT00086944
Drug: ifosfamide
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00086944
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00086944
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01442532
Drug: JNJ-38518168 (30 mg)
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type=range, unit=mg, number=30, form=tablet, route=oral use, in single and multiple doses for 14 days
Study: NCT01442532
Drug: JNJ-38518168 (10 mg)
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type=range, unit=mg, number=10, form=tablet, route=oral use, in single and multiple doses for 14 days
Study: NCT01442532
Drug: JNJ-38518168 (3 mg)
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type=range, unit=mg, number=3, form=tablet, route=oral use, in single and multiple doses for 14 days
Study: NCT01442532
Drug: Midazolam and JNJ-38518168
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam: Type=exact, unit=mg, number=2.5, form=oral solution; route=oral use, on Days 1 and 15; JNJ-38518168: Type=exact, unit=mg, number=30, form=tablet, route=oral use, once daily from Day 2 through Day 15
Study: NCT01066884
Drug: erlotinib [Tarceva]
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 150mg po daily
Study: NCT00729326
Drug: exenatide
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: subcutaneous injection (5mcg or 10mcg), twice a day